应用遗传改造的沙门菌介导肿瘤治疗的研究进展

肿瘤是机体在各种致瘤因子作用下,局部组织细胞异常增生所形成的赘生物。肿瘤治疗一直是临床上的一个难题,而放疗、化疗和手术等常规的肿瘤治疗方法均具有明显的局限性。早期研究发现某些厌氧菌或兼性厌氧菌具有抗肿瘤效应,例如兼性厌氧菌鼠伤寒沙门氏菌可以通过某些机制选择性定殖于肿瘤并抑制肿瘤生长,其应用于肿瘤治疗具有许多潜在的优势。过去的一二十年里,已有不少研究者通过遗传操作减弱沙门菌毒力,提高其定殖肿瘤的靶向性,或以减毒沙门菌作为载体向肿瘤靶向递呈各种治疗分子,并在许多动物试验中观察到遗传改造沙门菌的良好抗肿瘤效应。随着沙门菌抗肿瘤研究的不断深入,应用遗传改造的沙门菌有希望成为一条更有效的肿瘤治疗途径。本文将从沙门菌的抗肿瘤机制、遗传改造的沙门菌介导肿瘤治疗的研究进展和目前研究存在的问题等方面进行综述。     

沙门菌用于肿瘤生物治疗的研究进展

沙门菌(Salmonella)是用于抗肿瘤生物治疗很有前景的一种生物反应调节剂(biological response modifier, BRM)。鼠伤寒沙门菌(Salmonella typhimurium)是肿瘤生物治疗研究中最为常用的沙门菌之一。沙门菌可以在肿瘤细胞中定植,通过激活抗肿瘤免疫应答、诱导肿瘤细胞死亡等途径抑制肿瘤细胞的生长及转移。沙门菌可与其他抗肿瘤疗法联合使用,增强化疗药物的作用,也可作为抗肿瘤制剂的载体。现就沙门菌用于肿瘤的生物治疗作一概述。     

鼠伤寒沙门氏菌asd基因的克隆及序列分析

以鼠伤寒沙门氏茵标准株基因组DNA作为模板,用PCR的方法扩增鼠伤寒沙门氏菌的asd基因并克隆入质粒pUCl9,并对其进行测序,序列与献报道一致。同时将质粒pYA248上的链球菌asd基因进行了置换,观察了分别含有链球菌asd基因与鼠伤寒沙门氏菌asd基因的质粒在减毒鼠伤寒沙门氏菌X4072中的生长情况,结果表明含有鼠伤寒沙门氏菌的asd基因的高拷贝质粒pUCl9的菌株生长情况更好。为完善染色体／质粒平衡致死系统,构建减毒鼠伤寒沙门氏活菌疫苗奠定了基础。     

鼠伤寒沙门菌动物模型活体成像技术的研究进展

鼠伤寒沙门菌的体内实验有利于开展食物中毒、胃肠炎、伤寒热等肠道传染病的防治。由于在活体内检测鼠伤寒沙门菌的动态变化存在瓶颈,使细菌致病机制的研究、疫苗及药物研发滞后。近年来应用小动物成像技术在活体中追踪转化了荧光素酶基因的鼠伤寒沙门菌越来越受到人们关注,综述该技术的应用现状及缺憾之处。     

减毒鼠伤寒沙门菌体内定位分析…

分析减毒鼠伤寒沙门菌口服感染后在小鼠体内定位的情况.将构建的红色荧光蛋白(RFP)原核质粒pYA33-DsRed,以电穿孔法转化减毒鼠伤寒沙门菌X4550,重组菌命名为X4550(33-DsRed).重组菌分别感染巨噬细胞RAW264.7和骨髓源树突状细胞(BMDC),并用流式细胞术检测红色荧光细胞荧光强度.此外,以不同剂量重组菌口服免疫BALB/c小鼠,并于免疫后1d、2d、3d、5d、7d取小鼠脾、肝、肠系膜淋巴结(MLN)、派伊尔氏结(PP)、腹股沟淋巴结(ILN)细胞,检测各组织器官中的红色荧光阳性细胞百分率.重组菌对RAW264.7细胞和BMDC均具有良好的侵袭力.口服小鼠后,第1d,仅在MLN及PP中检测到RFP阳性细胞,其中PP中阳性细胞达到1.4%;第2 d,在ILN中达到0.4%;第3 d,各个组织器官中RFP阳性细胞均有上升趋势,此时在脾、肝中也检测到RFP阳性细胞.第5 d,RFP阳性细胞均减少,第7 d则未检测到任何RFP阳性细胞.减毒鼠伤寒沙门菌具有良好的侵袭力,其黏膜移行方式以及对免疫组织器官靶向定位性,在优化黏膜疫苗以及提高疫苗免疫效力等方面都具有重要作用.     

减毒鼠伤寒沙门菌三型分泌表达系统的构建及其特性

为开发新型重组减毒鼠伤寒沙门菌口服活疫苗载体,本研究以pYA3493质粒为基础,用鼠伤寒沙门菌sopE_(Nt100)基因及其启动子替代原有的P_(trc)启动子,构建沙门菌三型分泌表达载体pYA-sopE_(Nt100);再将质粒pYA-sopE_(Nt100)电转入沙门菌ΔcrpΔasd SL1344,构建减毒鼠伤寒沙门菌ΔcrpΔasd SL1344(p YA-sop E_(Nt100))三型分泌表达系统,研究其生物学特性,进一步将报告基因egfp克隆入sop E基因下游,构建重组菌株ΔcrpΔasd SL1344(p YA-sop E_(Nt100)-egfp),感染Vero细胞,用Western blotting分析该系统递呈外源抗原的能力。PCR、酶切及测序结果表明,减毒鼠伤寒沙门菌ΔcrpΔasd SL1344(p YA-sop E_(Nt100))三型分泌表达系统构建成功;生物学特性鉴定结果表明,其血清型与亲本株Δcrp SL1344及野生株SL1344保持一致;其生化特性与亲本株基本相近,但与野毒株相比发生明显变化;生长速度也更为缓慢;重组菌株ΔcrpΔasd SL1344(p YA-sop E_(Nt100))的LD50较野生株SL1344降低了7.0×104倍;Western blotting结果发现,重组菌培养上清中能检测到Sop E_(Nt100)-egfp融合蛋白(37 k Da);重组菌株感染Vero细胞后,可以同时检测到Sop E_(Nt100)-egfp融合蛋白(37 k Da)和EGFP蛋白(27 k Da)。以上结果证实,本研究成功构建了新型减毒鼠伤寒沙门菌ΔcrpΔasd(p YA-sop E_(Nt100))三型分泌表达系统,其能够有效递呈外源抗原,该重组菌株有潜力作为安全、稳定、高效表达外源基因的口服重组活疫苗载体。     

临床和非临床分离沙门菌的菌型分布及对抗生素的耐药性研究

目的：探讨沙门菌在腹泻病人粪便、外环境污水和部分动物标本中的菌型分布及其对抗生素的耐药性。方法：采用血清学方法对沙门菌进行分群和分型,采用K—B法进行抗生素耐药性测定。结果：410份临床腹泻病人标本和514份非临床标本共检出沙门菌93株,检出率为10．1％,其菌型分布为：腹泻病人粪便中检出的均为B群鼠伤寒沙门菌(6／93),非临床标本中的菌型主要为C2群纽波特沙门菌(72／93),还有E1群伦敦沙门菌(7／93)、B群鼠伤寒沙门菌(2／93)和未定型(6／93)。87株沙门菌对青霉素的耐药率最高(96．5％),其次为SMZ TMP(73．6％),未发现对新霉素、链霉素、四环素和阿米卡星的耐药株。结论：实验结果可为研究我省沙门菌的菌型分布及其对抗生素的耐药性提供参考;临床上应加强对鼠伤寒沙门菌引起腹泻的监测。     

鼠伤寒沙门菌rtsB基因缺失株的构建及其生物学特性

【背景】鼠伤寒沙门菌(Salmonella typhimurium)是一种重要的人畜共患病原菌,严重危害养殖业及人类健康。调控蛋白在病原菌的生存及感染过程中发挥重要作用。【目的】构建鼠伤寒沙门菌调控基因rtsB缺失株和互补株,分析调控蛋白RstB对鼠伤寒沙门菌生物学特性和致病性的影响。【方法】利用Red同源重组的方法构建鼠伤寒沙门菌SAT52的rtsB基因缺失株,并利用互补质粒构建互补株。然后比较分析野生株SAT52、缺失株?rtsB和互补株C?rtsB的生长特性、运动性、生物被膜形成能力、黏附入侵能力、胞内存活能力及致病性的差异。【结果】缺失rtsB基因不影响SAT52的生长速度,但导致运动能力增强,生物被膜形成能力减弱。细胞感染试验结果表明,rtsB基因有助于鼠伤寒沙门菌对Hela细胞的黏附入侵及RAW264.7细胞内的存活。动物试验结果表明rtsB基因缺失显著降低鼠伤寒沙门菌的致病力。【结论】rtsB基因在鼠伤寒沙门菌感染过程中发挥重要作用,可为阐释鼠伤寒沙门菌的致病机制提供参考。     

表达幽门螺杆菌黏附素保守区的减毒鼠伤寒沙门氏菌株的构建

为构建表达幽门螺杆菌（Hp）黏附素保守区（AB）的无抗性减毒鼠伤寒沙门氏菌疫苗,采用缺失腺苷酸环化酶基因（Δcya）、环腺苷酸受体蛋白基因（Δcrp）以及天冬氨酸β-半醛脱氢酶基因（Δasd）的鼠伤寒沙门菌（X4072）作为宿主,将编码AB的基因插入Asd⁺的组成型表达载体pYA248,通过两次转化引入宿主菌,构建了表达AB基因平衡致死的减毒鼠伤寒沙门重组菌X4072（pYA248-AB）,采用桥联法ELISA测定X4072（pYA248-AB）培养上清液和裂解上清液中AB的抗原性,参照Meacock叙述的方法及重组菌生长曲线的测定来确定重组菌株的稳定性,通过C57BL/6小鼠口服测定半致死量来确定重组菌的安全性。成功构建了表达AB的减毒鼠伤寒沙门菌重组菌株S.typhimurium X4072(pYA248-AB),桥联法ELISA测定表明重组菌X4072（pYA248-AB）培养上清中AB的含量高于菌体裂解液,重组菌pYA248-AB在没有选择压力的情况下培养100代,随机挑选的重组菌全部都能生长,且在ELISA测定AB抗原时均显阳性。重组菌的生长曲线测定表明,X4072（pYA248）和X4072（pYA248-AB）的生长状态基本一致;口服重组菌株X4072(pYA248-AB)1.0×10¹⁰cfu.30d后,C57BL/6存活率仍为100%。成功构建了表达AB的无抗性的减毒鼠伤寒沙门菌疫苗X4072（pYA248-AB）,体外实验表明重组质粒是稳定的,动物实验证明重组菌株是安全的;为防治幽门螺杆菌感染提供了口服活菌疫苗候选株。     

伤寒沙门菌动物模型研究进展

目前伤寒沙门菌引起的人类伤寒仍是一种严重危害人类健康的疾病,且近年来多重耐药伤寒沙门菌株频频出现,使伤寒的治疗更加棘手.由于该菌具有严格的宿主特异性,又缺乏理想的动物模型,其致病机制的研究、疫苗及药物的研发受制约.新近研究发现,免疫系统人源化小鼠模型和诱导型一氧化氮合酶基因敲除小鼠模型可用于伤寒沙门菌的体内实验.本文就其应用现状及缺憾作一综述.     

Bacterial copper- and zinc-cofactored superoxide dismutase contributes to the pathogenesis of systemic salmonellosis

Copper/zinc-cofactored superoxide dismutase ([Cu,Zn]-SOD) has been found in the periplasm of many bacterial species but its biological function is unknown. Here we report the cloning and characterization of sodC , encoding [Cu,Zn]-SOD, from Salmonella typhimurium . The predicted protein sequence shows only 58% identity to Escherichia coli SodC, and from this its chromosomal location and its immediate proximity to a phage gene, sodC , in Salmonella is speculated to have been acquired by bacteriophage-mediated horizontal transfer from an unknown donor. A sodC mutant of S . typhimurium was unimpaired on aerobic growth in rich medium but showed enhanced sensitivity in vitro to the microbicidal action of superoxide. S . typhimurium , S . choleraesuis and S . dublin sodC mutants showed reduced lethality in a mouse model of oral infection and persisted in significantly lower numbers in livers and spleens after intraperitoneal infection, suggesting that [Cu,Zn]-SOD plays a role in pathogenicity, protecting Salmonella against oxygen radical-mediated host defences. There was, however, no observable difference compared with wild type in the interaction of sodC mutants with porcine pleural, mouse peritoneal or J774 macrophages in vitro , perhaps reflecting the hierarchical capacity of different macrophage lines to kill Salmonella , the most efficient overwhelming the proposed protective effect of periplasmic SOD.     

雷公藤红素抗肿瘤作用及机制研究进展

雷公藤红素是我国传统中药雷公藤中的天然活性成分,具有抗类风湿、抗炎、抗肿瘤等多种生物学活性。近年来,雷公藤红素由于低毒、多靶点、广谱性等优势,在抗肿瘤治疗中备受关注。雷公藤红素可以通过调控PI3K/AKT、NF-κB、MAPK和STAT3等多种信号通路抑制肿瘤增殖、侵袭和转移,诱导肿瘤细胞凋亡。综述了雷公藤红素的抗肿瘤作用及机制,以期促进雷公藤红素的深入研究与应用。     

Inhibition effect of pcDNA-tum-5 on the growth of S180 tumor

Tumor growth and metastasis depend on vessel formation, and inhibition of angiogenesis of tumor by production of anti-angiogenic drugs should be a promising approach for cancer therapy. Tumstatin is an angiogenesis inhibitor. The anti-angiogenic activity of tumstatin is localized to the 54–132 amino acids. The gene fragment encoding amino acids 45–132 of tumstatin (tum-5) was subcloned into pcDNA3.1 (pcDNA-tum5). Tum-5 protein could be expressed and secreted in CHO cells after transfection. The conditioned medium (containing tum-5 protein) from the transfectant has an anti-angiogenic effect on HUVEC cells in vitro. The anti-tumor effect of pcDNA-tum5 on mice bearing S180 tumors was evaluated. The results showed that pcDNA-tum-5 has a significant inhibition activity in the growth of the tumors. This study suggests that the gene delivery of tum-5 may be an effective strategy for cancer therapy.     

Introduction of 65 kDa antigen of Mycobacterium tuberculosis to cancer cells enhances anti-tumor effect of BCG therapy

Bacillus Calmette Guerin (BCG) immunotherapy has anti-tumorigenic effects against bladder cancer. To improve the efficacy of BCG therapy, we introduced the gene encoding the 65 kDa heat shock protein (hsp) of Mycobacterium tuberculosis into a mouse malignant melanoma cell line (B16). An expression vector harboring the 65 kDa antigen gene was transfected into B16 using Lipofectamine, then expression of the antigen was confirmed by RT-PCR and Western blotting. Several cell lines expressing 65 kDa antigen were established (B16/65 kDa). We also established a control cell line transfected with the vector alone (B16/con). All cell lines (B16, B16/con, B16/65 kDa) were injected intraperitoneally into syngeneic mice with or without BCG prior immunization and the development of tumor ascites was examined. To analyze the mechanism of the anti-tumor effect, CD4 T cells or CD8 T cells were depleted in vivo by administering the corresponding monoclonal antibody. B16/65k Da expressed the 65 kDa hsp of M. tuberculosis. The tumor growth of B16/65 kDa was slightly retarded in naive mice, but significantly inhibited by BCG. The anti-tumor effect was totally abrogated in mice deficient in CD4 T cells, suggesting that CD4 T cells are involved in this process. The 65 kDa hsp of M. tuberculosis was expressed after gene transduction in a malignant melanoma cell line and significantly enhanced the anti-tumor effect of BCG immunotherapy. CD4 T cells play an important role in this anti-tumor effect.     

The tumor immunosuppressive microenvironment impairs the therapy of anti-HER2/neu antibody

It has been well established that immune surveillance plays critical roles in preventing the occurrence and progression of tumor. More and more evidence in recent years showed the host anti-tumor immune responses also play important roles in the chemotherapy and radiotherapy of cancers. Our previous study found that tumor- targeting therapy of anti-HER2/neu mAb is mediated by CD8⁺ T cell responses. However, we found here that enhancement of CD8⁺ T cell responses by combination therapy with IL-15R/IL-15 fusion protein or anti-CD40, which are strong stimultors for T cell responses, failed to promote the tumor therapeutic effects of anti-HER2/neu mAb. Analysis of tumor microenviornment showed that tumor tissues were heavily infiltrated with the immunosuppressive macrophages and most tumor infiltrating T cells, especially CD8⁺ T cells, expressed high level of inhibitory co-signaling receptor PD-1. These data suggest that tumor microenvironment is dominated by the immunosuppressive strategies, which thwart anti-tumor immune responses. Therefore, the successful tumor therapy should be the removal of inhibitory signals in the tumor microenvironment in combination with other therapeutic strategies.     

<Emphasis Type="Italic">Salmonella typhimurium</Emphasis> engineered to produce CCL21 inhibit tumor growth

Intravenously-applied bacteria tend to accumulate in tumors and can sporadically lead to tumor regression. Systemic administration of attenuated Salmonella typhimurium is safe and has shown no significant adverse effects in humans. The purpose of this study was to test the hypothesis that engineering S. typhimurium to express a chemokine, CCL21, would increase anti-tumor activity. We engineered an attenuated strain of S. typhimurium to produce the chemokine CCL21. Attenuated S. typhimurium expressing CCL21 significantly inhibited the growth of primary tumors and pulmonary metastases in preclinical models of multi-drug-resistant murine carcinomas, while control bacteria did not. Histological analysis of tumors showed marked inflammatory cell infiltrates in mice treated with CCL21-expressing but not control bacteria. Levels of cytokines and chemokines known to be induced by CCL21 [e.g., interferon-γ (INFγ), CXCL9, and CXCL10] were significantly elevated in tumors of mice treated with CCL21-expressing but not control S. typhimurium. The anti-tumor activity was found to be dependent on CD4- and CD8-expressing cells, based on antibody-mediated in vivo immuno-depletion experiments. Anti-tumor activity was achieved without evidence of toxicity. In summary, chemokine-expressing, attenuated bacteria may provide a novel approach to cancer immunotherapy for effective and well-tolerated in vivo delivery of immunomodulatory proteins. Markus Loeffler and John C. Reed should be considered senior authors.     

成纤维细胞激活蛋白alpha与肿瘤免疫抑制的研究进展

成纤维细胞激活蛋白alpha（Fibroblast activation protein-alpha,FAP-alpha）是一种跨膜丝氨酸蛋白酶,高度表达在90 %的上皮性肿瘤的 间质--肿瘤相关成纤维细胞（Tumor association fibroblast,TAF）上。FAPalpha在促进上皮性肿瘤的恶性进展中起着十分重要的作用, 近年来研究发现,FAP琢在肿瘤微环境中发挥免疫抑制的作用。研究FAPalpha在肿瘤免疫抑制中的作用,已成为肿瘤研究的新的热 点。为基于以FAP-alpha为靶标的抗肿瘤免疫治疗提供参考,本文围绕引起肿瘤免疫抑制的因素、FAPalpha与肿瘤免疫抑制的研究进展 以及FAP-alpha在肿瘤的发展进程的作用作一综述。     

肿瘤靶向治疗的新型细胞载体

肿瘤靶向性病毒作为一种特殊的肿瘤治疗药物和基因治疗载体近年来已得到长足发展,许多高效、靶向性病毒载体已被相继研究开发,但仍不能满足临床上肿瘤靶向治疗的需要,如何将这些靶向病毒准确而高效地运输到肿瘤病变部位仍然未得到充分解决.细胞因子诱导杀伤细胞(cytokine-inducedkillercells,CIK)作为肿瘤的细胞治疗方法之一已成功地在临床上得到了广泛应用.最近科学家使用CIK细胞作为病毒运载工具,成功地将病毒运载到肿瘤组织部位并显示出高效的抗肿瘤作用,该方法为病毒运输定位于肿瘤病变部位找到了突破口,实验资料显示其具有潜在的应用价值.